BofA lowered the firm’s price target on Waters (WAT) to $350 from $410 and keeps a Neutral rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especially around China, the analyst tells investors in a preview for the group.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAT:
- Waters price target lowered to $350 from $400 at Barclays
- Waters upgraded to Overweight from Sector Weight at KeyBanc
- Wingstop initiated, CarMax upgraded: Wall Street’s top analyst calls
- Waters upgraded to Outperform from Neutral at Baird
- Balanced Outlook: Waters Corporation’s Growth Prospects and Risks Underpin Hold Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue